We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
Read MoreHide Full Article
Key Takeaways
INSM's Arikayce filing seeks approval for newly diagnosed MAC lung disease patients.
The FDA granted priority review, with a decision expected by Jan. 28, 2027.
Arikayce sales rose 7% to $214.4 million in first-half 2026.
Insmed (INSM - Free Report) announced that the FDA has accepted a regulatory filing seeking label expansion for Arikayce in mycobacterium avium complex (MAC) lung disease.
The FDA has granted the filing priority review, shortening the review period by four months. A final decision is expected by Jan. 28, 2027.
The regulatory filing is seeking approval for Arikayce as part of a combination antibacterial drug regimen for newly diagnosed MAC lung disease patients. It would also fulfil the post-marketing requirement associated with the drug’s existing accelerated approval.
Arikayce was approved by the FDA in 2018 under the accelerated pathway to treat refractory MAC lung disease as part of a combination antibacterial drug regimen in adult patients with limited or no alternative treatment options. It is approved for similar indications in Europe and Japan.
The filing is supported by results from the phase IIIb ENCORE study, which met its primary endpoint of improvement in the respiratory symptom score (RSS), a patient-reported outcome measure. The study also achieved several key secondary endpoints.
Insmed intends to engage with regulatory authorities in Japan during the fourth quarter of 2026 regarding Arikayce’s label expansion.
INSM Stock Performance
Shares of Insmed have underperformed the industry in the year-to-date period, as seen in the chart below.
Image Source: Zacks Investment Research
Arikayce: A Top-line Driver for Insmed
Arikayce was the first marketed product in Insmed’s portfolio. Despite its approval for a limited treatment population, sales of the drug have continued to grow, driven by encouraging demand across all markets.
Sales of the drug rose 7% year over year to $214.4 million in first-half 2026. For the full year, the company expects to record sales between $450 million and $470 million, suggesting 6% year-over-year growth at the midpoint.
The label expansion has been viewed positively by investors, given the potential for a significant expansion in Arikayce’s addressable market. The company has previously estimated the total addressable market (TAM) for refractory MAC lung disease at around 30,000 patients across the United States, Europe and Japan. Insmed estimates that the broader MAC lung disease population across these markets could exceed 200,000 patients. If approved for use in newly diagnosed patients, the expanded indication could significantly increase Arikayce’s addressable market and commercial potential.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share (EPS) of 25 cents. Over the same period, EPS estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have gained 84% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, EPS estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost nearly 16% year-to-date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
View the Zacks #1 Rank List
Image: Bigstock
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
Key Takeaways
Insmed (INSM - Free Report) announced that the FDA has accepted a regulatory filing seeking label expansion for Arikayce in mycobacterium avium complex (MAC) lung disease.
The FDA has granted the filing priority review, shortening the review period by four months. A final decision is expected by Jan. 28, 2027.
The regulatory filing is seeking approval for Arikayce as part of a combination antibacterial drug regimen for newly diagnosed MAC lung disease patients. It would also fulfil the post-marketing requirement associated with the drug’s existing accelerated approval.
Arikayce was approved by the FDA in 2018 under the accelerated pathway to treat refractory MAC lung disease as part of a combination antibacterial drug regimen in adult patients with limited or no alternative treatment options. It is approved for similar indications in Europe and Japan.
The filing is supported by results from the phase IIIb ENCORE study, which met its primary endpoint of improvement in the respiratory symptom score (RSS), a patient-reported outcome measure. The study also achieved several key secondary endpoints.
Insmed intends to engage with regulatory authorities in Japan during the fourth quarter of 2026 regarding Arikayce’s label expansion.
INSM Stock Performance
Shares of Insmed have underperformed the industry in the year-to-date period, as seen in the chart below.
Image Source: Zacks Investment Research
Arikayce: A Top-line Driver for Insmed
Arikayce was the first marketed product in Insmed’s portfolio. Despite its approval for a limited treatment population, sales of the drug have continued to grow, driven by encouraging demand across all markets.
Sales of the drug rose 7% year over year to $214.4 million in first-half 2026. For the full year, the company expects to record sales between $450 million and $470 million, suggesting 6% year-over-year growth at the midpoint.
The label expansion has been viewed positively by investors, given the potential for a significant expansion in Arikayce’s addressable market. The company has previously estimated the total addressable market (TAM) for refractory MAC lung disease at around 30,000 patients across the United States, Europe and Japan. Insmed estimates that the broader MAC lung disease population across these markets could exceed 200,000 patients. If approved for use in newly diagnosed patients, the expanded indication could significantly increase Arikayce’s addressable market and commercial potential.
INSM’s Zacks Rank
Insmed currently carries a Zacks Rank #3 (Hold).
Insmed, Inc. Price
Insmed, Inc. price | Insmed, Inc. Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) and AC Immune (ACIU - Free Report) . While PGEN sports a Zacks Rank #1 (Strong Buy), ACIU carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share (EPS) of 25 cents. Over the same period, EPS estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have gained 84% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, EPS estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost nearly 16% year-to-date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.